News

Metronidazole needed for complete pelvic inflammatory disease coverage

View on the News

Do we really need the metro?

When practicing doctors see data like these, they are going to say, "Look, we want to cover everything," so they opt for the metronidazole, said Dr. David A. Eschenbach.

But that’s a problem because doxycycline causes GI upset. When metronidazole is used as well, you have major GI upset in a huge number of people; a third of your patients may drop out of treatment because of it.

Also, adding metronidazole has not seemed to make any difference in outpatients with mild PID. They have colonization with these organisms, but they are not really in deep, so you may not need metronidazole. For inpatients who have a pretty established anaerobic flora, you may need to use metronidazole.

Dr Eschenbach is professor and chair of obstetrics and gynecology at the University of Washington in Seattle. He said he had no relevant financial disclosures.


 

AT IDSOG

BERNALILLO, N.M. – It’s necessary to use metronidazole in addition to doxycycline and a cephalosporin to cover all the bacteria species associated with pelvic inflammatory disease, according to an analysis of 198 endometrial biopsy isolates from 170 women with the condition.

"The coadministration of a cephalosporin with doxycycline for women with PID provides coverage for all anaerobic pathogens except Prevotella species. The addition of metronidazole is necessary to provide coverage for these anaerobic gram-negative rods," investigators from the University of Pittsburgh concluded.

Twelve percent of the women had Prevotella species in their endometrium that were resistant to both ceftriaxone and doxycycline, but not metronidazole.

Dr. Sharon Hillier

The Centers for Disease Control and Prevention currently recommends an injectable cephalosporin and oral doxycycline for outpatient PID, but lets clinicians decide whether to include metronidazole.

"If you are going to cover the spectrum of organisms that are there, you really have to add the metronidazole," said senior investigator Sharon L. Hillier, Ph.D., professor of obstetrics, gynecology, and reproductive sciences in the division of infectious diseases at the university.

But "there’s reticence to prescribe it in addition to doxycycline because of the GI upset and lack of tolerance. The concern is that people might not finish their antimicrobials and get worse. It’s truly a conundrum; we don’t have a good alternative to metronidazole," Dr. Hillier said at the annual meeting of the Infectious Diseases Society of Obstetrics and Gynecology.

Also, "there aren’t longitudinal data yet that show that women with untreated Prevotella have worse outcomes. There haven’t been data suggesting that failure to cover those has long-term infertility sequelae. My own view is that we probably should use metronidazole. The bottom line is that no two antibiotics cover everything," she said.

Biopsies from 65 women – all outpatients 15-40 years old with clinical PID diagnoses – grew out one or more organisms. In all, 17 types or species of bacteria were isolated.

Gardnerella vaginalis, Atopobium vaginae, and Prevotella and Lactobacillus species made up 81% of the isolates.

Ceftriaxone was effective for all of them except the Prevotella, while metronidazole was effective against only the Prevotella. Doxycycline susceptibilities ranged from 47% for A. vaginae to 82% for G. vaginalis.

With the exception of Prevotella, ceftriaxone and doxycycline "are effective against many of the anaerobic and facultative bacteria associated with" PID, the researchers concluded.

aotto@frontlinemedcom.com

Recommended Reading

New strain of norovirus wreaks havoc
MDedge ObGyn
Anti-TNF agents vary in ability to cross placenta
MDedge ObGyn
BMI does not influence PPI effectiveness in GERD or erosive esophagitis
MDedge ObGyn
Risk of HCV transmission very low in monogamous heterosexual couples
MDedge ObGyn
Amitriptyline eases functional dyspepsia symptoms
MDedge ObGyn
CDC investigates Cyclospora outbreak
MDedge ObGyn
High BMI appears to cause gallstones
MDedge ObGyn
Antibiotics, PPIs may fuel community-associated C. difficile
MDedge ObGyn
Study identifies distinct microbiome in Crohn’s intestinal submucosa
MDedge ObGyn
Vedolizumab shows promise in Crohn’s, ulcerative colitis
MDedge ObGyn